Mauna Kea Technologies

About

Mauna Kea Technologies specializes in designing, developing, and selling optical biopsy devices and tools.

Paris,Ile-de-France,France
101 - 250

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $30M
Industries: Biotechnology,Medical,Medical Device
Founded date: Jan 1, 2000
Number Of Employee: 101 - 250
Operating Status: Active
Stock Symbol: epa:MKEA

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval for a wide range of applications in the United States and more than 40 countries around the World.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

6

$30M €27M

Mauna Kea Technologies has raised a total of $30M €27M in funding over 2 rounds. Their latest funding was raised on May 31, 2023 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
May 31, 2023	Post-IPO Equity	—	—	—	—	Detail
Sep 24, 2021	Post-IPO Equity	€12.50M	2	—	—	Detail
Dec 16, 2019	Post-IPO Equity	€7.50M	1	Johnson & Johnson Innovation – JJDC	—	Detail
Feb 8, 2017	Post-IPO Debt	€7M	1	IPF Partners	—	Detail
Jul 15, 2011	IPO	—	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

3

6

Mauna Kea Technologies is funded by 6 investors. IPF Partners and Psilos Group are the most recent investors.

Investor Name	Lead Investor	Funding Round
IPF Partners	Yes	Post-IPO Debt
Psilos Group	Yes	Series B
Armistice Capital	—	Post-IPO Equity
Johnson & Johnson Innovation – JJDC	—	Post-IPO Equity
Creadev	—	Series B
Seventure Partners	—	Series B